Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
Paula R. Clemens, Vamshi K. Rao, Anne M. Connolly, et al.
Journal of Neuromuscular Diseases (2022) Vol. 9, Iss. 4, pp. 493-501
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Amplifying gene expression with RNA-targeted therapeutics
Olga Khorkova, Jack Stahl, Aswathy Joji, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 539-561
Open Access | Times Cited: 70
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Jillian Belgrad, Hassan H. Fakih, Anastasia Khvorova
Nucleic Acid Therapeutics (2024) Vol. 34, Iss. 2, pp. 52-72
Closed Access | Times Cited: 35
Phase 1/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy
Hirofumi Komaki, Eri Takeshita, Katsuhiko Kunitake, et al.
Cell Reports Medicine (2025), pp. 101901-101901
Open Access | Times Cited: 2
Drug development progress in duchenne muscular dystrophy
Jiexin Deng, Junshi Zhang, Keli Shi, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 57
Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology
Man Amanat, Christina L. Nemeth, Amena Smith Fine, et al.
Pharmaceutics (2022) Vol. 14, Iss. 11, pp. 2389-2389
Open Access | Times Cited: 47
Duchenne muscular dystrophy: pathogenesis and promising therapies
Mengyuan Chang, Yong Cai, Zihui Gao, et al.
Journal of Neurology (2023) Vol. 270, Iss. 8, pp. 3733-3749
Closed Access | Times Cited: 27
Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study
Paula R. Clemens, Vamshi K. Rao, Anne M. Connolly, et al.
Journal of Neuromuscular Diseases (2023) Vol. 10, Iss. 3, pp. 439-447
Open Access | Times Cited: 23
Next steps for the optimization of exon therapy for Duchenne muscular dystrophy
Galina Filonova, Annemieke Aartsma‐Rus
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 2, pp. 133-143
Open Access | Times Cited: 17
Non‐coding RNAs to treat vascular smooth muscle cell dysfunction
Simon Brown, Eftychia Klimi, Wilfried A.M. Bakker, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 8
Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO
Umme Sabrina Haque, Melissa Kohut, Toshifumi Yokota
Current Research in Toxicology (2024) Vol. 7, pp. 100182-100182
Open Access | Times Cited: 8
Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights
Edanur Ersöz, Devrim Demir Dora
Drug Development Research (2024) Vol. 85, Iss. 4
Open Access | Times Cited: 7
Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy
Gökçe Eser, Haluk Topaloğlu
Genes (2022) Vol. 13, Iss. 7, pp. 1241-1241
Open Access | Times Cited: 26
A Brief Review of Duchenne Muscular Dystrophy Treatment Options, with an Emphasis on Two Novel Strategies
Ahlke Heydemann, Maria Siemionow
Biomedicines (2023) Vol. 11, Iss. 3, pp. 830-830
Open Access | Times Cited: 14
Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy
LeighAnn Y. Vincik, Alexandra D. Dautel, A. Staples, et al.
Advances in Therapy (2024) Vol. 41, Iss. 4, pp. 1338-1350
Closed Access | Times Cited: 5
Gene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments
Cédric Happi Mbakam, Jacques P. Tremblay
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 10, pp. 905-920
Closed Access | Times Cited: 10
Treating neuromuscular diseases: unveiling gene therapy breakthroughs and pioneering future applications
Yu‐Fu Wu, Jun‐An Chen, Yuh‐Jyh Jong
Journal of Biomedical Science (2025) Vol. 32, Iss. 1
Open Access
Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration
Maria Siemionow, Grzegorz Biegański, Adam Niezgoda, et al.
Stem Cell Reviews and Reports (2023) Vol. 19, Iss. 8, pp. 2724-2740
Open Access | Times Cited: 8
ATS Core Curriculum 2022. Pediatric Pulmonary Medicine: Updates in pediatric neuromuscular disease
Carmen Leon‐Astudillo, Caroline U. A. Okorie, Michael McCown, et al.
Pediatric Pulmonology (2023) Vol. 58, Iss. 7, pp. 1866-1874
Closed Access | Times Cited: 8
Evaluation of Chemically Modified Nucleic Acid Analogues for Splice Switching Application
Bao T. Le, Suxiang Chen, Rakesh N. Veedu
ACS Omega (2023) Vol. 8, Iss. 51, pp. 48650-48661
Open Access | Times Cited: 8
Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy
Sarah Engelbeen, Daniel O’Reilly, David van de Vijver, et al.
Nucleic Acid Therapeutics (2023) Vol. 33, Iss. 6, pp. 348-360
Open Access | Times Cited: 7
Longitudinal data of serum creatine kinase levels and motor, pulmonary, and cardiac functions in 337 patients with Duchenne muscular dystrophy
Hiroyuki Awano, Yoshinori Nambu, Chieko Itoh, et al.
Muscle & Nerve (2024) Vol. 69, Iss. 5, pp. 604-612
Open Access | Times Cited: 2
Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy
Maria Siemionow, Katarzyna Bocian, Katarzyna Bożyk, et al.
Stem Cell Reviews and Reports (2024) Vol. 20, Iss. 7, pp. 1819-1829
Open Access | Times Cited: 2
Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic–Intraosseous Administration
Adam Niezgoda, Grzegorz Biegański, Jacek Wachowiak, et al.
Archivum Immunologiae et Therapiae Experimentalis (2023) Vol. 71, Iss. 1
Open Access | Times Cited: 6
Efficacy of N-163 strain ofAureobasidium pullulans-produced beta-glucan in improving muscle strength and function in patients with Duchenne muscular dystrophy; Results of a 6-month non-randomised open-label linear clinical trial
Kadalraja Raghavan, Thanasekar Sivakumar, Sudhakar S Bharatidasan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Recent updates on therapeutic targeting of lipoprotein(a) with RNA interference
Aravind Sekhar, Ashani Kuttan, Richard A. Lange
Current Opinion in Cardiology (2024)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top